Regional Capability of Different Regions Within China

Regional Capability of Different Regions Within China

RootsAnalysis
RootsAnalysis
2 min read

The key parameters that, we believe, are likely to have an influence on the regional capability of biopharmaceutical manufacturing, and hence, were taken into consideration, include:

Number of CMOs: This parameter takes into account the number of biopharmaceutical CMOs headquartered in a particular geography; during our research, we were able to identify 39 such players that were based in China.Number of Clinical Sites: This parameter takes into account the total number of clinical sites located in a particular geography that are conducting trials and enrolling patients for clinical studies; we came across 3,850 clinical sites that were based in China, including Hong Kong and Taiwan.Number of Clinical Trials: This parameter takes into account the total number of completed / ongoing / planned clinical trials across different geographical regions. Presently, 1,935 biopharmaceuticals focused clinical trials have been / are being / are planned to be conducted in China, including Hong Kong and Taiwan.Number of Patients Enrolled: This parameter takes into account the total number of patients enrolled (1,470,388) in various biopharmaceuticals focused clinical trials that were / are registered in different regions across China, including Hong Kong and Taiwan.Number of Manufacturing Facilities: This parameter takes into account the number of biopharmaceuticals manufacturing facilities located in a particular geography; a total of 65 such facilities are located in China.Number of API / FDF Manufacturing Facilities: This parameter takes into account the number of API / FDF manufacturing facilities located in a particular region.Number of Clinical / Commercial Manufacturing Facilities: This parameter take into account the number of clinical / commercial manufacturing facilities located in a particular region.Installed Capacity: This parameter takes into account the installed contract manufacturing capacity (in terms of liters) of service providers in a particular region. The total, annual, installed capacity in China for biopharmaceutical manufacturing is 0.3 million liters.

Discussion (0 comments)

0 comments

No comments yet. Be the first!